sciencenewsnet.in

High expression levels of the gene TRIM63 can serve as an accurate and sensitive biomarker of a subtype of kidney cancer known as microphthalmia-associated transcription factor family aberration-associated renal cell carcinomas — or MiTF renal cell carcinoma.

It’s important to distinguish MiTF from other subtypes of kidney cancers — clear cell, papillary and chromophobe — because these tumors may not respond well to standard, front-line treatments and may respond better to other approaches.

Research Results

Exploring Impact of Surgery Delays for Clinical Renal Cell Carcinoma Patients during the COVID-19 Pandemic

February 11, 2021 sarah Jonas ASCO, COVID-19, New Jersey, Renal Cell Carcinoma, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, Rutgers University, RWJBarnabas Health

During the peak of the COVID-19 pandemic, several elective surgeries for renal cell carcinoma, the most common type of kidney cancer, were delayed with unknown impact on outcomes for patients. Researchers at Rutgers Cancer Institute of New Jersey explored the impact of surgery delays for these patients throughout the United States by utilizing the National Cancer Database to explore outcomes of patients who underwent surgery up to and after three months post diagnosis.

Research Results

Deep Look at Immune Cells in Patients’ Tumors Reveals Insights on Timing for Treatment Combinations

September 8, 2020 sarah Jonas Immunotherapy, Kidney Cancer, Radiation, RCC, Renal Cell Carcinoma, Sterotactic Radiation, T cell

It’s clear that radiation therapy, or radiotherapy, an approach used to treat cancer since the early 20th century, can be an effective companion to newer, immune-stimulating approaches known as immunotherapy. Research from a team from Roswell Park Comprehensive Cancer Center explains how radiation helps boost the immune system’s ability to fight cancer in combination with immune checkpoint inhibitors — and provides new evidence that the timing of these therapies can make a big difference in how effectively they work together.

Research Results

Novel targeted drug induced positive response for patients with von Hippel-Lindau disease–associated kidney cancer

May 28, 2020 sarah Jonas Cancer, Kidney Cancer, Renal Cell Carcinoma

In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)–associated renal cell carcinoma (RCC).

Research Results

Diagnostic Biomarkers Uncovered for Rare Kidney Cancer

April 14, 2020 sarah Jonas biomarkers, Cancer, Kidney Cancer, Renal Cell Carcinoma

Using next-generation RNA sequencing techniques, a team of scientists from the University of Michigan Rogel Cancer Center has uncovered the gene signature of chromophobe renal cell carcinoma (ChRCC) and have extensively tested the expression of three new biomarkers. The subtype is the third most common type of renal cell carcinoma, comprising about 5% of cases.